ANTICORPS ANTI-STEAP2, CONJUGUÉS ANTICORPS-MÉDICAMENT, ET MOLÉCULES BISPÉCIFIQUES DE LIAISON À L'ANTIGÈNE QUI SE LIENT À STEAP2 ET CD3, ET LEURS UTILISATIONS
RUDGE, John,DELFINO, Frank,HABER, Lauric,SMITH, Eric,KIRSHNER, Jessica R.,CRAWFORD, Alison,NITTOLI, Thomas
申请号：
USUS2017/053111
公开号：
WO2018/058001A1
申请日:
2017.09.22
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The protein known as six-transmembrane epithelial antigen of prostate 2 (STEAP2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human IgG antibodies that bind to human STEAP2 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both STEAP2 and CD3 and activate T cells via the CD3 complex in the presence of STEAP2 -expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds humanSTEAP2. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing STEAP2. The bispecific antigen-binding molecules of the invention are useful for the treatment of prostate diseases and disorders in which an upregulated or induced STEAP2 -targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of prostate cancers, including castrate-resistant prostate cancer. The present invention also includes anti-STEAP2 antibody drug conjugates which inhibit tumor growth in vivo.La protéine connue sous le nom d'antigène épithélial six-transmembranaires de la prostate 2 (STEAP2) est hautement exprimée dans le cancer de la prostate et est associée à l'expression d'autres gènes associés au cancer de la prostate. La présente invention concerne de nouveaux anticorps IgG humains pleine longueur qui se lient à la STEAP2 humaine (anticorps monospécifiques). La présente invention concerne également de nouveaux anticorps bispécifiques (bsAbs) qui se lient à la fois à la STEAP2 et à au CD3 et activent les lymphocytes T par l'intermédiaire du comp
